Treatment of GERD and proton pump inhibitor use in the elderly: Practical approaches and frequently asked questions

American Journal of Gastroenterology

Volumn 106, Issue 3, 2011, Pages 386-392

  Scholl, Shannon ^a   Dellon, Evan S ^a   Shaheen, Nicholas J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYANOCOBALAMIN; ESOMEPRAZOLE; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE;

ABDOMINAL PAIN; ACHLORHYDRIA; AGE DISTRIBUTION; AGING; ANTICOAGULANT THERAPY; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER RISK; CEREBROVASCULAR ACCIDENT; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CORONARY ARTERY DISEASE; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; FALL RISK; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; HEART INFARCTION; HEARTBURN; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; HYPERGASTRINEMIA; LOW DRUG DOSE; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SCREENING TEST; STABLE ANGINA PECTORIS; STENT THROMBOSIS; STOMACH ULCER; VITAMIN BLOOD LEVEL;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; ASPIRIN; BARRETT ESOPHAGUS; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HEARTBURN; HIP FRACTURES; HUMANS; INTESTINAL ABSORPTION; MIDDLE AGED; OBESITY; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; POPULATION SURVEILLANCE; PREVALENCE; PROTON PUMP INHIBITORS; TICLOPIDINE; VITAMIN B 12;

EID: 79952344414     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.409     Document Type: Article

References (77)

1. Zhu H, Pace F, Sangaletti O et al. Features of symptomatic gastroesophageal reflux in elderly patients. Scand J Gastroenterol 1993;28:235-8. (Pubitemid 23080681)
2. Manabe N, Yoshihara M, Sasaki A et al. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol 2002;17:949-54.
3. Collen MJ, Abdulian JD, Chen YK. Gastroesophageal reflux disease in the elderly: more severe disease that requires aggressive therapy. Am J Gastroenterol 1995;90:1053-7.
4. Johnson DA, Fennerty MB. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology 2004;126:660-4. (Pubitemid 38298313)
5. Raiha I, Hietanen E, Sourander L. Symptoms of gastro-oesophageal reflux disease in elderly people. Age Ageing 1991;20:365-70.
6. Horiuchi A, Nakayama Y, Hidaka N et al. Lowdose propofol sedation for diagnostic esophagogastroduodenoscopy: results in 10,662 adults. Am J Gastroenterol 2009;104:1650-5.
7. Qureshi WA, Zuckerman MJ, Adler DG et al. ASGE guideline: modifications in endoscopic practice for the elderly. Gastrointest Endosc 2006;63:566-9.
8. El-Serag HB, Aguirre TV, Davis S et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99:1877-83. (Pubitemid 39421227)
9. Hillman LC, Chiragakis L, Shadbolt B et al. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther 2008;27:321-6.
10. Nguyen DM, El-Serag HB, Henderson L et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009;7:1299-304.
11. Lippmann QK, Crockett SD, Dellon ES et al. Quality of life in GERD and Barrett's esophagus is related to gender and manifestation of disease. Am J Gastroenterol 2009;104:2695-703.
12. Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98:S8-14.
13. Jalving M, Koornstra JJ, Wesseling J et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341-8. (Pubitemid 44571564)
14. Dial S, Alrasadi K, Manoukian C et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-8. (Pubitemid 38925116)
15. Laheij RJ, Sturkenboom MC, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60. (Pubitemid 39411203)
16. Slotwiner-Nie PK, Brandt LJ. Infectious diarrhea in the elderly. Gastroenterol Clin North Am 2001;30:625-35. (Pubitemid 32880444)
17. Landahl S, Andersson T, Larsson M et al. Pharmacokinetic study of omeprazole in elderly healthy volunteers. Clin Pharmacokinet 1992;23:469-76.
18. Flouvat B, Delhotal-Landes B, Cournot A et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993;36:467-9. (Pubitemid 23344159)
19. Hasselgren G, Hassan-Alin M, Andersson T et al. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001;40:145-50. (Pubitemid 32242796)
20. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003;63:2739-54. (Pubitemid 38049991)
21. Hampel H, Abraham NS, El-Serag HB. Metaanalysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199-211. (Pubitemid 41076753)
22. Jacobson BC, Somers SC, Fuchs CS et al. Bodymass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006;354:2340-8. (Pubitemid 43801279)
23. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44.
24. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60.
25. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75.
26. Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose: the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009;54:1149-53.
27. Neubauer H, Engelhardt A, Kruger JC et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel: a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol 2010;56:91-7.
28. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-8.
29. Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010;170:704-10.
30. Bhatt B. Is there an interaction between clopidogrel and proton pump inhibitors: the COGENT trial. Clinical Cardiology, 104th edn.
31. US Food and Drug Administration. Information for Healthcare Professionals: Update to the Labeling of Clopidogrel Bisulfate (Marketed as Plavix) to Alert Healthcare Professionals About a Drug Interaction With Omeprazole (Marketed as Prilosec and Prilosec OTC)http://www.fdagov/Drugs/ DrugSafety/Postmarket-DrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm (17 November 2009).
32. Labenz J, Petersen KU, Rosch W et al. A summary of Food and Drug Administrationreported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2003;17:1015-9. (Pubitemid 36560801)
33. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392-413.
34. Humphries TJ. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig Dis Sci 1991;36:1665-9.
35. Sutfin T, Balmer K, Bostrom H et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989;11:176-84. (Pubitemid 19064843)
36. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28. (Pubitemid 26238200)
37. Taha AS, Angerson WJ, Prasad R et al. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment Pharmacol Ther 2007;26:1171-8. (Pubitemid 47480957)
38. Ekstrom P, Carling L, Wetterhus S et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996;31:753-8. (Pubitemid 26255041)
39. Targownik LE, Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993-2003. Clin Gastroenterol Hepatol 2006;4:1459-66.
40. Agrawal NM, Campbell DR, Safdi MA et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000;160:1455-61. (Pubitemid 30327448)
41. Blandizzi C, Tuccori M, Colucci R et al. Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients. Drugs Aging 2008;25:197-208. (Pubitemid 351363752)
42. Yeomans N, Lanas A, Labenz J et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008;103:2465-73.
43. Eisen GM, Baron TH, Dominitz JA et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002;55:775-9.
44. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89. (Pubitemid 40397259)
45. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo- controlled trial. Lancet 2005;366:1607-21.
46. Becker RC, Scheiman J, Dauerman HL et al. Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol 2009;54:2261-76.
47. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71. (Pubitemid 28550691)
48. Mauri L, Hsieh WH, Massaro JM et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9. (Pubitemid 46376802)
49. Cutlip DE, Baim DS, Ho KK et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71. (Pubitemid 32322224)
50. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30. (Pubitemid 40617065)
51. Aoki J, Lansky AJ, Mehran R et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2009;119:687-98.
52. Sianos G, Papafaklis MI, Daemen J et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol 2007;50:573-83. (Pubitemid 47198999)
53. Cotton PB, Lehman G, Vennes J et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-93.
54. Freeman ML, Nelson DB, Sherman S et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-18. (Pubitemid 26314443)
55. Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc 1994;40:458-62. (Pubitemid 24235576)
56. Collet JP, Montalescot G, Blanchet B et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004;110:2361-7. (Pubitemid 39407340)
57. Vicenzi MN, Meislitzer T, Heitzinger B et al. Coronary artery stenting and non-cardiac surgery: a prospective outcome study. Br J Anaesth 2006;96:686-93. (Pubitemid 43786682)
58. Johnson DA, Winters C, Spurling TJ et al. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987;9:23-7. (Pubitemid 17035252)
59. Inadomi JM, Sampliner R, Lagergren J et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176-86. (Pubitemid 36231623)
60. Williamson WA, Ellis FH Jr, Gibb SP et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991;151:2212-6.
61. Spechler SJ, Robbins AH, Rubins HB et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984;87:927-33. (Pubitemid 14040468)
62. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am 1997;26:487-94. (Pubitemid 27453229)
63. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53. (Pubitemid 29374530)
64. Wang KK, Wongkeesong M, Buttar NS. American Gastroenterological Association technical review on the role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005;128:1471-505. (Pubitemid 40712197)
65. Overholt BF, Lightdale CJ, Wang KK et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-98. (Pubitemid 41383764)
66. Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-88.
67. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992;14:288-92.
68. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994;120:211-5.
69. Schenk BE, Festen HP, Kuipers EJ et al. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996;10:541-5. (Pubitemid 26254797)
70. Koop H. Review article: Metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992;6:399-406.
71. Yang YX, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53. (Pubitemid 46021498)
72. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83. (Pubitemid 44306164)
73. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis- related fractures. CMAJ 2008;179:319-26.
74. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-9.
75. Graziani G, Como G, Badalamenti S et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 1995;10:1376-80.
76. Targownik LE, Lix LM, Leung S et al. Protonpump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904.
77. US Food and Drug Administration. FDA Drug Safety Communication: Possible Increased Risk of Fractures of the Hip, Wrist, and Spine With the Use of Proton Pump Inhibitors http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ucm213206.htm (25 May 2010).